Value (or Outcome) based Arrangements for new high cost therapies

FEATURING: NEIL MINKOFF, MD, KEN BOYLE, DC, MBA, FIAMA, JIM CLEMENT, DEIRDRE PARSONS

How will we pay for new high-cost medicines to treat diseases? Is there a way to better align incentives of biopharmaceutical manufacturers, health insurers, and health care delivery systems? “Value Based” or “Outcome Based” arrangements hold promise for aligning payments to results, but come with a host of implementation challenges ranging from pricing policy barriers to a need for high-quality data to define and measure the results, and the costs, of drugs delivered. A number of industry players are taking bold steps to test these models in the market and are learning firsthand what works, what needs improvement, and how data and outcomes can potentially power new models for drug reimbursement and pricing.

0:00:00 Introduction to the Session and Speakers
0:07:45 What changes are required in information sharing / data collection?
0:13:33 Neil discusses real-world experience working with payers to produce drugs.
0:18:35 Prescribers vs Payers
0:22:39 Value (or Outcome) Based Contracts
0:33:55 What data is required to determine Outcomes?
0:43:42 Transitioning demonstration projects to broader contracts
0:46:44 Audience Questions & Outro